CD8A and neoplasm: In 2017, vaccines using personalized mRNA induced polyfunctional CD8+ and CD4+ T-cell responses in 24.8% and 48.0% of the vaccinated neoantigens and led to tumor regression or prolonged stable disease condition [19].